The FDA introduced the unique device identifier system in 2013 to improve the tracking of medical devices from distribution to use. Since then, the agency has systematically established compliance dates for the healthcare industry to implement the new labeling requirements.
The agency sorts all medical devices or products into three classifications based on risk. Class I devices, like bandages, are low risk and subject to the least amount of regulatory controls. Class II devices, such as power wheelchairs, are deemed higher risk than Class I devices and require greater regulatory controls. Class III devices, like replacement heart valves, bring the most risk and are subject to the highest level of regulatory control.
The FDA places the responsibility for UDI compliance on the “labeler” of a medical device, or the owner of the brand. If the manufacturer does not sell the products under its own brand, it is not responsible for the UDI implementation.
More articles on medical devices:
Medical device industry agrees to FDA’s device user fees to raise regulatory funding
Researchers develop new method to transfer device data to smartphones
Concussion monitoring device earns FDA clearance
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
